A proprietary process to identify small molecules for activating progenitor cells
Discovery in the right context
Traditional drug screening uses cells that may not reflect the complex biology of tissue-specific cell types in the body, especially for progenitor cells. We develop primary progenitor cell assays that are designed to maintain these cells in their natural state to increase the likelihood of successful drug discovery and translation into an effective, tissue-specific therapeutic.
Decoding and controlling activation pathways for progenitor cells
Using our insights into progenitor cell signaling and aging, we work to identify biological pathways that may activate a specific progenitor cell. We then select and apply proprietary small molecules to modulate the chosen biological pathways to activate these progenitors.